164 related articles for article (PubMed ID: 38085895)
1. Central Nervous System Lymphoma.
Schaff L
Continuum (Minneap Minn); 2023 Dec; 29(6):1710-1726. PubMed ID: 38085895
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
3. Central Nervous System Lymphomas.
Grommes C
Continuum (Minneap Minn); 2020 Dec; 26(6):1476-1494. PubMed ID: 33273169
[TBL] [Abstract][Full Text] [Related]
4. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
5. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
[TBL] [Abstract][Full Text] [Related]
6. Primary CNS lymphoma and neurologic complications of hematologic malignancies.
Nayak L; Pentsova E; Batchelor TT
Continuum (Minneap Minn); 2015 Apr; 21(2 Neuro-oncology):355-72. PubMed ID: 25837901
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
Roschewski M; Hodson DJ
Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
10. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Holte H; Leppä S; Björkholm M; Fluge O; Jyrkkiö S; Delabie J; Sundström C; Karjalainen-Lindsberg ML; Erlanson M; Kolstad A; Fosså A; Ostenstad B; Löfvenberg E; Nordström M; Janes R; Pedersen LM; Anderson H; Jerkeman M; Eriksson M
Ann Oncol; 2013 May; 24(5):1385-92. PubMed ID: 23247661
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma.
Ferreri AJM; Calimeri T; Cwynarski K; Dietrich J; Grommes C; Hoang-Xuan K; Hu LS; Illerhaus G; Nayak L; Ponzoni M; Batchelor TT
Nat Rev Dis Primers; 2023 Jun; 9(1):29. PubMed ID: 37322012
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Involvement in Peripheral T Cell Lymphoma.
Chihara D; Oki Y
Curr Hematol Malig Rep; 2018 Feb; 13(1):1-6. PubMed ID: 29374824
[TBL] [Abstract][Full Text] [Related]
13. [Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2023; 64(6):490-496. PubMed ID: 37407473
[TBL] [Abstract][Full Text] [Related]
14. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
[TBL] [Abstract][Full Text] [Related]
15. Prevention and management of secondary central nervous system lymphoma.
Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
[TBL] [Abstract][Full Text] [Related]
16. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based management of primary and secondary CNS lymphoma.
Khwaja J; Nayak L; Cwynarski K
Semin Hematol; 2023 Nov; 60(5):313-321. PubMed ID: 38135609
[TBL] [Abstract][Full Text] [Related]
18. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
19. Consolidation Therapy in Primary Central Nervous System Lymphoma.
Kim P; Omuro A
Curr Treat Options Oncol; 2020 Jul; 21(9):74. PubMed ID: 32725379
[TBL] [Abstract][Full Text] [Related]
20. Central Nervous System Lymphoma: Novel Therapies.
Fortin Ensign SP; Gathers D; Wiedmeier JE; Mrugala MM
Curr Treat Options Oncol; 2022 Jan; 23(1):117-136. PubMed ID: 35182298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]